<DOC>
	<DOCNO>NCT01003977</DOCNO>
	<brief_summary>Single center registry patient receive Xience V everolimus-eluting stent Washington Hospital Center , primary objective ass clinical success safety 30 day , 6 month 1 year post-implantation .</brief_summary>
	<brief_title>Registry Experience Washington Hospital Center , DES - Xience V</brief_title>
	<detailed_description>Interventional cardiology revolutionize invention stent , initially bare-metal stent ( BMS ) recently drug-eluting stent ( DES ) . The everolimus eluting , Xience V stent show promising result randomize clinical trial , demonstrate reduction clinical angiographic restenosis comparison BMS , comparable clinically-driven target lesion revascularization rate comparison sirolimus-eluting stent . While registry data available outside United States , important collect `` real-world '' data regard stent usage outcome United States . In study propose follow patient receive least one Xience VÂ® Stent least 1 year post initial stent implantation .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients , male female , &gt; 18 year age Patients receive least one Xience V drugeluting stent Washington Hospital Center Patients receive another type DES ( Xience V ) bare metal stent time initial Xience V stent implantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>